nach oben

Erschienen in:

28.06.2018 | Original Paper

Immunoreactivity patterns of tight junction proteins are useful for differential diagnosis of human salivary gland tumors

verfasst von: Tomoyuki Aoyama, Akira Takasawa, Masaki Murata, Makoto Osanai, Kenichi Takano, Tadashi Hasagawa, Norimasa Sawada

Erschienen in: Medical Molecular Morphology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The expression pattern of tight junction proteins (TJPs) varies among organs and tumor types. In this study, we examined the immunoreactivity of claudin (CLDN)-1, -4, and -7, and JAM-A in salivary gland tumors (SGTs) by histological types and cell types to estimate their usefulness as differential diagnostic markers. Immunoreactivity of CLDN1 was higher in ductal epithelium cells of SGTs than in non-tumor tissues. Conversely, immunoreactivity of CLDN1 was significantly decreased in basal/myoepithelium cells of SGTs compared with that in non-tumor tissues. There was no significant difference between the immunoreactivity of CLDN1 in benign tumors and that in malignant tumors. Immunoreactivity of CLDN4, CLDN7, and JAM-A in ductal epithelium cells was higher in many SGTs than in non-tumor tissues. There was a difference depending on the histological type of SGT in immunoreactivity of CLDN4, CLDN7, and JAM-A in basaloid/myoepithelial cells. It was possible to classify SGTs by a hierarchical clustering using immunoreactivity of TJPs. The results suggest that an immunohistochemical marker panel including these TJPs may be useful for differential diagnosis of SGTs and that CLDN1 is associated with tumorigenesis of SGTs.

Anderson JM, Cereijido M (2001) Tight junctions, 2nd edn. CRC Press, Boca Raton, pp 1–18

Tsukita S, Furuse M, Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2:285–293CrossRefPubMed

Chiba H, Osanai M, Murata M, Kojima T, Sawada N (2008) Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778:588–600CrossRefPubMed

Severson EA, Parkos C (2009) Structural determinants of junctional adhesion molecule A (JAM-A) function and mechanisms of intracellular signaling. Curr Opin Cell Biol 21:701–707CrossRefPubMedPubMedCentral

Takano K, Kojima T, Sawada N, Himi T (2014) Role of tight junctions in signal transduction: an update. EXCLI J 13:1145–1162PubMedPubMedCentral

Sawada N (2013) Tight junction-related human diseases. Pathol Int 63:1–12CrossRefPubMed

Osanai M, Takasawa A, Murata M, Sawada N (2017) Claudins in cancer: bench to bedside. Pflugers Arch 469:55–67CrossRefPubMed

Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N (1997) Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol 136:1239–1247CrossRefPubMedPubMedCentral

Smedley JG III, Uzal FA, McClane BA (2007) Identification of a prepore large-complex stage in the mechanism of action of Clostridium perfringens enterotoxin. Infect Immun 75:2381–2390CrossRefPubMedPubMedCentral

10.

Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B, Tsukita S, Leder G, Adler G, Gress TM (2001) Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121:678–684CrossRefPubMed

11.

Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P, Sukumar S (2004) Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 164:1627–1633CrossRefPubMedPubMedCentral

12.

Santin AD, Cané S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S (2005) Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 65:4334–4342CrossRefPubMed

13.

Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ, Burnett A, Tognon G, Bandiera E, Pecorelli S (2007) Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Clin Cancer Res 13:3339–3346CrossRefPubMed

14.

Maeda T, Murata M, Chiba H, Takasawa A, Tanaka S, Kojima T, Masumori N, Tsukamoto T, Sawada N (2012) Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer. Prostate 72:351–360CrossRefPubMed

15.

Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65:9603–9606CrossRefPubMed

16.

Kominsky SL (2006) Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 8:1–11CrossRefPubMed

17.

Goetsch L, Haeuw JF, Bear-Larvor C, Gonzalez A, Zanna L, Malissard M, Lepecquet AM, Robert A, Bailly C, Broussas M, Corvaia N (2012) A novel role for junctional adhesion moleculea-A in tumor proliferation: modulation by an anti-JAM-A monoclonal antibody. Int J Cancer 132:1463–1474CrossRefPubMed

18.

Murakami M, Giampietro C, Giannotta M, Corada M, Torselli I, Orsenigo F, Cocito A, d’Ario G, Mazzarol G, Confalonieri S, Di Fiore PP, Dejana E (2011) Abrogation of junctional adhesion molecule-A expression induces cell apoptosis and reduces breast cancer progression. PLoS One 6:e21242CrossRefPubMedPubMedCentral

19.

El-Naggar AK (2017) Tumors of the salivary glands. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds) World Health Organization Classification of Tumors. WHO classification of head and neck tumours, 4th edn. International Agency for Research on Cancer Press, Lyon, pp 160–202

20.

Baker OJ (2010) Tight junctions in salivary epithelium. J Biomed Biotechnol 2010:278948CrossRefPubMedPubMedCentral

21.

Baker OJ (2016) Current trends in salivary gland tight junctions. Tissue Barriers 4:e1162348CrossRefPubMedPubMedCentral

22.

Tang VW, Goodenough DA (2003) Paracellular ion channel at the tight junction. Biophys J 84:1660–1673CrossRefPubMedPubMedCentral

23.

Kriegs JO, Homann V, Kinne-Saffran E, Kinne RK (2007) Identification and subcellular localization of paracellin-1 (claudin-16) in human salivary glands. Histochem Cell Biol 128:45–53CrossRefPubMed

24.

Lourenço SV, Coutinho-Camillo CM, Buim ME, Uyekita SH, Soares FA (2007) Human salivary gland branching morphogenesis: morphological localization of claudins and its parallel relation with developmental stages revealed by expression of cytoskeleton and secretion markers. Histochem Cell Biol 128:361–369CrossRefPubMed

25.

Maria OM, Kim JW, Gerstenhaber JA, Baum BJ, Tran SD (2008) Distribution of tight junction proteins in adult human salivary glands. J Histochem Cytochem 56:1093–1098CrossRefPubMedPubMedCentral

26.

Ewert P, Aguilera S, Alliende C, Kwon YJ, Albornoz A, Molina C, Urzúa U, Quest AF, Olea N, Pérez P, Castro I, Barrera MJ, Romo R, Hermoso M, Leyton C, González MJ (2010) Disruption of tight junction structure in salivary glands from Sjögren’s syndrome patients is linked to proinflammatory cytokine exposure. Arthritis Rheum 62:1280–1289CrossRefPubMed

27.

Mellas RE, Leigh NJ, Nelson JW, McCall AD, Baker OJ (2015) Zonula occludens-1, occludin and E-cadherin expression and organization in salivary glands with Sjögren’s Syndrome. J Histochem Cytochem 63:45–56CrossRefPubMedPubMedCentral

28.

Abe A, Takano K, Kojima T, Nomura K, Kakuki T, Kaneko Y, Yamamoto M, Takahashi H, Himi T (2016) Interferon-gamma increased epithelial barrier function via upregulating claudin-7 expression in human submandibular gland duct epithelium. J Mol Histol 47:353–363CrossRefPubMed

29.

Aro K, Rosa LE, Bello IO, Soini Y, Mäkitie AA, Salo T, Leivo I (2011) Expression pattern of claudins 1 and 3—an auxiliary tool in predicting behavior of mucoepidermoid carcinoma of salivary gland origin. Virchows Arch 458:341–348CrossRefPubMed

30.

Abd El-Ghani SF, Kasem RF, Ghallab NA, Shaker OG (2013) Detection of claudin-4 in salivary gland neoplasms (a study utilizing RT-PCR and immunohistochemistry). J Oral Pathol Med 42:781–787CrossRefPubMed

31.

Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E (1986) Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopahtol 409:127–147CrossRef

32.

Keira Y, Takasawa A, Murata M, Nojima M, Takasawa K, Ogino J, Higashiura Y, Sasaki A, Kimura Y, Mizuguchi T, Tanaka S, Hirata K, Sawada N, Hasegawa T (2015) An immunohistochemical marker panel including claudin-18, maspin, and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens. Virchows Arch 466:265–277CrossRefPubMed

33.

Mi Jeong Kwon (2013) emerging roles of claudins in human cancer. Int J Mol Sci 14:18148–18180CrossRefPubMedPubMedCentral

34.

Huang J, Zhang L, He C, Qu Y, Li J, Zhang J, Du T, Chen X, Yu Y, Liu B, Zhu Z (2015) Claudin-1 enhances tumor proliferation and metastasis by regulating cell anoikis in gastric cancer. Oncotarget 6:1652–1665PubMed

35.

Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG, Fukamachi H, Ito Y (2010) Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 138:255–265CrossRefPubMed

36.

Pope JL, Ahmad R, Bhat AA, Washington MK, Singh AB, Dhawan P (2014) Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenomatous polyposis coli-mediated colon tumorigenesis. Mol Cancer 13:167CrossRefPubMedPubMedCentral

37.

Bezdekova M, Brychtova S, Sedlakova E, Langova K, Brychta T, Belej K (2012) Analysis of Snail-1, E-cadherin and claudin-1 expression in colorectal adenomas and carcinomas. Int J Mol Sci 13:1632–1643CrossRefPubMedPubMedCentral

38.

Huo Q, Kinugasa T, Wang L, Huang J, Zhao J, Shibaguchi H, Kuroki M, Tanaka T, Yamashita Y, Nabeshima K, Iwasaki H, Kuroki M (2009) Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer. Anticancer Res 29:851–857PubMed

39.

Weber CR, Nalle SC, Tretiakova M, Rubin DT, Turner JR (2008) Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest 88:1110–1120CrossRefPubMedPubMedCentral

40.

Tőkés A-M, Kulka J, Paku S, Szik Á, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z (2005) Claudin-1, -3 and – 4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7:R296–R305CrossRefPubMedPubMedCentral

41.

Myal Y, Leygue E, Blanchard AA (2010) Claudin 1 in breast tumorigenesis: revelation of a possible novel “claudin high” subset of breast cancers. J Biomed Biotechnol 2010:956897CrossRefPubMedPubMedCentral

42.

Tokés AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z (2005) Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7:R296–R305CrossRefPubMedPubMedCentral

43.

Yoon CH, Kim MJ, Park MJ, Park IC, Hwang SG, An S, Choi YH, Yoon G, Lee SJ (2009) Claudin-1 acts through c-ABl-PKCdelta signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem 285:226–233CrossRefPubMedPubMedCentral

44.

Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS, Hwang SG, An S, Yoon G, Gye MC, Yi JM, Kim MJ, Lee SJ (2012) Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 32:4873–4882CrossRefPubMed

45.

Chao YC, Pan SH, Yang SC, Yu SL, Che TF, Lin CW, Tsai MS, Chang GC, Wu CH, Wu YY, Lee YC, Hong TM, Yang PC (2009) Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179:123–133CrossRefPubMed

46.

Tzelepi VN, Tsamandas AC, Vlotinou HD, Vagianos CE, Scopa CD (2008) Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol 21:22–30CrossRefPubMed

47.

Zwanziger D, Badziong J, Ting S, Moeller LC, Schmid KW, Siebolts U, Wickenhauser C, Dralle H, Fuehrer D (2015) The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness. Endocr Relat Cancer 22:819–830CrossRefPubMed

48.

Goetsch L, Haeuw JF, Beau-Larvor C, Gonzalez A, Zanna L, Malissard M, Lepecquet AM, Robert A, Bailly C, Broussas M, Corvaia N (2013) A novel role for junctional adhesion molecule-A in tumor proliferation: modulation by an anti-JAM-A monoclonal antibody. Int J Cancer 132:1463–1474CrossRefPubMed

49.

Takasawa A, Murata M, Takasawa K, Ono Y, Osanai M, Tanaka S, Nojima M, Kono T, Hirata K, Kojima T, Sawada N (2016) Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer. Sci Rep 6:33582CrossRefPubMedPubMedCentral

50.

Akimoto T, Takasawa A, Murata M, Kojima Y, Takasawa K, Nojima M, Aoyama T, Hiratsuka Y, Ono Y, Tanaka S, Osanai M, Hasegawa T, Saito T, Sawada N (2016) Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1, -4, -7, occludin and JAM-A, in human cervical adenocarcinoma. Histol Histopathol 31:921–931PubMed

Titel: Immunoreactivity patterns of tight junction proteins are useful for differential diagnosis of human salivary gland tumors
verfasst von: Tomoyuki Aoyama
Akira Takasawa
Masaki Murata
Makoto Osanai
Kenichi Takano
Tadashi Hasagawa
Norimasa Sawada
Publikationsdatum: 28.06.2018
Verlag: Springer Japan
Erschienen in: Medical Molecular Morphology / Ausgabe 1/2019
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI: https://doi.org/10.1007/s00795-018-0199-6

Springer Medizin

Immunoreactivity patterns of tight junction proteins are useful for differential diagnosis of human salivary gland tumors

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

BRI2 as an anti-Alzheimer gene

Positive correlation between the density of macrophages and T-cells in undifferentiated sarcoma

Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes

Physical exercise alters hepatic morphology of low-density lipoprotein receptor knockout ovariectomized mice

Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification

Methods for array tomography with correlative light and electron microscopy

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie